Rosetta Genomics to be Featured on The Balancing Act® Airing on Lifetime Television Network

   Rosetta Genomics to be Featured on The Balancing Act® Airing on Lifetime
                              Television Network

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Jan. 30, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 30, 2013 /PRNewswire/ -- Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that the Company will be
featured on The Balancing Act^®, a daily morning talk show on the Lifetime^®
Television Network devoted to supporting women. The segment featuring Rosetta
Genomics will air on the Lifetime Television Network on February 4^th,
February 27th and March 5th from 7:00-8:00 a.m. Eastern Time.

The featured piece highlights Rosetta Genomics' novel microRNA-based molecular
diagnostics assays and underscores the growing need for more advanced
diagnostic tools, such as the Company's lead product, miRview^® mets^2, to
identify cancers and to optimize treatment options. The video may be viewed
in the Investor Relations section of Company's website at
www.rosettagenomics.com.

"We are delighted to have our miRview^® product line of microRNA-based
molecular diagnostic assays showcased on the Balancing Act. We believe this
featured segment will increase the visibility and knowledge of our highly
accurate oncology diagnostic assays," stated Kenneth A. Berlin, President and
Chief Executive Officer of Rosetta Genomics.

The Balancing Act^® is an innovative television program illuminating new ways
for women to achieve success in all areas of their lives. The program, which
runs every morning from 7:00–8:00 a.m. ET and PT on Lifetime^® Television
Network, is dedicated to creating trusted solutions for women facing today's
greatest challenges.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets^2 accurately identifies the primary tumor
type in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets^2 test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to
Rosetta's commercialization of its miRview^® assays, particularly miRview^®
mets^2any details regarding the time of airing of the segment specified
above, as well as the contents of said segment and Rosetta's capitalization of
its microRNA platform constitute forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:

LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

or

Bruce Voss
(310) 691-7100
bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Website: http://www.rosettagenomics.com
 
Press spacebar to pause and continue. Press esc to stop.